# FDA Inspection 1167413 - StimLabs, LLC - April 07, 2022

Source: https://www.keypedia.com/records/fda_inspections/stimlabs-llc/f1f9b7ff-d9b9-41a7-ae84-e4d1d16784bc
Source feed: FDA_Inspections

> FDA Inspection 1167413 for StimLabs, LLC on April 07, 2022. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1167413
- Company Name: StimLabs, LLC
- Inspection Date: 2022-04-07
- Classification: No Action Indicated (NAI)
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1167413 - 2022-04-07](https://www.keypedia.com/records/fda_inspections/stimlabs-llc/46f8f3cf-259f-4bcb-845a-7a7b4dda9093)
- [FDA Inspection 1167413 - 2022-04-07](https://www.keypedia.com/records/fda_inspections/stimlabs-llc/82b8d42a-132d-4866-8c40-1649cb5701fd)
- [FDA Inspection 1038774 - 2018-01-02](https://www.keypedia.com/records/fda_inspections/stimlabs-llc/ba736ec8-ede2-4f9f-822a-e41a2d402457)

Company: https://www.keypedia.com/companies/stimlabs-llc/def0d701-7a5e-4e9b-b6bb-bdcd6de509bf

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d